[Intravitreal ranibizumab therapy for choroidal neovascularization secondary to pathological myopia].

CONCLUSIONS: Intravitreal ranibizumab is an effective therapy in pathological myopia. Some patients experience deterioration of visual acuity despite of treatment. Orv. Hetil., 2017, 158(15), 579-586.
PMID: 28393596 [PubMed - in process]

Source: Orvosi Hetilap - April 1, 2017 Category: Journals (General) Authors: Lukács R, Sándor G, Resch M, Szabó A, Barcsay G, Ecsedy M, Szepessy Z, Nagy ZZ, Papp A Tags: Orv Hetil Source Type: research